ENBREL was approved for JIA in the U initial.S. In 1999. It is estimated through postmarketing data that 13 approximately, 847 pediatric patients have been treated with ENBREL globally through February 2009, accounting for approximately 44,600 patient-years of publicity. Postmarketing cases of malignancies have been reported in pediatric sufferers treated with ENBREL. Amgen and Wyeth are committed to patient safety and support the continuing evaluation of the potential risks and benefits of TNF blockers for patients who are prescribed these therapies. Both businesses maintain ongoing protection surveillance programs worldwide to examine all data sources available to them, and use regulatory agencies to upgrade the label as suitable based on emerging info.This article can be republished with kind permission from our friends at The Kaiser Family Foundation. You can view the entire Kaiser Daily Health Plan Record, search the archives, or sign up for email delivery of in-depth coverage of wellness policy developments, debates and discussions. The Kaiser Daily Wellness Policy Report is released for Kaisernetwork.org, a free assistance of The Henry J. Kaiser Family Foundation. Copyright 2009 Advisory Plank Kaiser and Company Family members Foundation.